OBJECTIVES: With this study we aimed to compare survival rates for children with Down syndrome in 2 time periods, 1 before prenatal screening (1988-1990) and 1 contemporaneous with screening (1998-2000), and to examine the frequency of comorbidities and their influence on survival rates. METHODS: Record-linkage was performed between the population-based Victorian Birth Defects Register and records of deaths in children up to 15 years of age collected under the auspice of the Consultative Council on Obstetric and Pediatric Mortality and Morbidity. Cases of Down syndrome were coded according to the presence or absence of comorbidities by using the International Classification of Diseases, Ninth Revision classification of birth defects. Kaplan-Meier survival functions and log rank tests for equality of survival distributions were performed. RESULTS: Of infants liveborn with Down syndrome in 1998-2000, 90% survived to 5 years of age, compared with 86% in the earlier cohort. With fetal deaths excluded, the proportion of isolated Down syndrome cases in the earlier cohort was 48.7% compared with 46.1% in the most recent cohort. In 1988-1990 there was at least 1 cardiac defect in 41.1% of cases and in 45.4% in 1998-2000. There was significant variation in survival rates for the different comorbidity groupings in the 1988-1990 cohort, but this was not so evident in the 1998-2000 cohort. CONCLUSIONS: Survival of children with Down syndrome continues to improve, and there is an overall survival figure of 90% to at least 5 years of age. It is clear from this study that prenatal screening technologies are not differentially ascertaining fetuses with Down syndrome and additional defects, because there has been no proportional increase in births of isolated cases with Down syndrome.
OBJECTIVES: With this study we aimed to compare survival rates for children with Down syndrome in 2 time periods, 1 before prenatal screening (1988-1990) and 1 contemporaneous with screening (1998-2000), and to examine the frequency of comorbidities and their influence on survival rates. METHODS: Record-linkage was performed between the population-based Victorian Birth Defects Register and records of deaths in children up to 15 years of age collected under the auspice of the Consultative Council on Obstetric and Pediatric Mortality and Morbidity. Cases of Down syndrome were coded according to the presence or absence of comorbidities by using the International Classification of Diseases, Ninth Revision classification of birth defects. Kaplan-Meier survival functions and log rank tests for equality of survival distributions were performed. RESULTS: Of infants liveborn with Down syndrome in 1998-2000, 90% survived to 5 years of age, compared with 86% in the earlier cohort. With fetal deaths excluded, the proportion of isolated Down syndrome cases in the earlier cohort was 48.7% compared with 46.1% in the most recent cohort. In 1988-1990 there was at least 1 cardiac defect in 41.1% of cases and in 45.4% in 1998-2000. There was significant variation in survival rates for the different comorbidity groupings in the 1988-1990 cohort, but this was not so evident in the 1998-2000 cohort. CONCLUSIONS: Survival of children with Down syndrome continues to improve, and there is an overall survival figure of 90% to at least 5 years of age. It is clear from this study that prenatal screening technologies are not differentially ascertaining fetuses with Down syndrome and additional defects, because there has been no proportional increase in births of isolated cases with Down syndrome.
Authors: Nansi S Boghossian; Jeffrey D Horbar; Joseph H Carpenter; Jeffrey C Murray; Edward F Bell Journal: J Pediatr Date: 2011-12-16 Impact factor: 4.406
Authors: M Loane; J E Given; J Tan; A Reid; D Akhmedzhanova; G Astolfi; I Barišić; N Bertille; L B Bonet; C C Carbonell; O Mokoroa Carollo; A Coi; J Densem; E Draper; E Garne; M Gatt; S V Glinianaia; A Heino; E Den Hond; S Jordan; B Khoshnood; S Kiuru-Kuhlefelt; K Klungsøyr; N Lelong; L R Lutke; A J Neville; L Ostapchuk; A Puccini; A Rissmann; M Santoro; I Scanlon; G Thys; D Tucker; S K Urhoj; H E K de Walle; D Wellesley; O Zurriaga; J K Morris Journal: PLoS One Date: 2021-08-27 Impact factor: 3.240
Authors: Logan Manikam; Anne G M Schilder; Monica Lakhanpaul; Peter Littlejohns; Emma C Alexander; Andrew Hayward Journal: Infection Date: 2020-03-14 Impact factor: 3.553